JP2020523332A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020523332A5 JP2020523332A5 JP2019568064A JP2019568064A JP2020523332A5 JP 2020523332 A5 JP2020523332 A5 JP 2020523332A5 JP 2019568064 A JP2019568064 A JP 2019568064A JP 2019568064 A JP2019568064 A JP 2019568064A JP 2020523332 A5 JP2020523332 A5 JP 2020523332A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkoxy
- substituted
- substituents selected
- fluoroalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 pyridadinyl Chemical group 0.000 claims 18
- 125000000217 alkyl group Chemical group 0.000 claims 13
- 125000003545 alkoxy group Chemical group 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 9
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 8
- 150000001875 compounds Chemical class 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 125000005843 halogen group Chemical group 0.000 claims 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 6
- 125000004076 pyridyl group Chemical group 0.000 claims 6
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 5
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 4
- 125000002393 azetidinyl group Chemical group 0.000 claims 4
- 229910052739 hydrogen Inorganic materials 0.000 claims 4
- 239000001257 hydrogen Substances 0.000 claims 4
- 125000002757 morpholinyl group Chemical group 0.000 claims 4
- 125000004193 piperazinyl group Chemical group 0.000 claims 4
- 125000003386 piperidinyl group Chemical group 0.000 claims 4
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 4
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000004414 alkyl thio group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001188 haloalkyl group Chemical group 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010002388 Angina unstable Diseases 0.000 claims 1
- 206010007556 Cardiac failure acute Diseases 0.000 claims 1
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000007814 Unstable Angina Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 230000001269 cardiogenic effect Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 201000004332 intermediate coronary syndrome Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 125000004043 oxo group Chemical group O=* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762517203P | 2017-06-09 | 2017-06-09 | |
| US62/517,203 | 2017-06-09 | ||
| PCT/US2018/036624 WO2018227058A1 (en) | 2017-06-09 | 2018-06-08 | Piperidinone formyl peptide 2 receptor agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020523332A JP2020523332A (ja) | 2020-08-06 |
| JP2020523332A5 true JP2020523332A5 (enExample) | 2021-07-26 |
| JP7098663B2 JP7098663B2 (ja) | 2022-07-11 |
Family
ID=62779077
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019568064A Active JP7098663B2 (ja) | 2017-06-09 | 2018-06-08 | ピペリジノンホルミルペプチド２受容体アゴニスト |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US11008301B2 (enExample) |
| EP (1) | EP3634955B1 (enExample) |
| JP (1) | JP7098663B2 (enExample) |
| KR (1) | KR102615095B1 (enExample) |
| CN (1) | CN110997652B (enExample) |
| ES (1) | ES2869129T3 (enExample) |
| WO (1) | WO2018227058A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10717708B2 (en) | 2015-12-10 | 2020-07-21 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| JP7094989B2 (ja) | 2017-06-09 | 2022-07-04 | ブリストル－マイヤーズ スクイブ カンパニー | シクロプロピルウレアホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
| EP3634956B1 (en) | 2017-06-09 | 2021-04-07 | Bristol-Myers Squibb Company | Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| WO2018227065A1 (en) * | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| WO2019173182A1 (en) | 2018-03-05 | 2019-09-12 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
| CN113166134B (zh) | 2018-11-26 | 2024-06-14 | 百时美施贵宝公司 | 作为甲酰肽2受体激动剂的吡咯烷酮衍生物 |
| EP4178946A1 (en) | 2020-07-09 | 2023-05-17 | Bristol-Myers Squibb Company | Oxopyrrolidine fpr2 agonists |
| ES2986512T3 (es) | 2020-07-09 | 2024-11-11 | Bristol Myers Squibb Co | Agonistas del receptor 2 del péptido formil pirazolona |
| WO2022035923A1 (en) | 2020-08-12 | 2022-02-17 | Bristol-Myers Squibb Company | Oxopyrrolidine urea fpr2 agonists |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7678913B2 (en) * | 2004-12-07 | 2010-03-16 | Portola Pharmaceuticals, Inc. | Ureas as factor Xa inhibitors |
| SG11201406629VA (en) | 2012-04-16 | 2014-11-27 | Allergan Inc | (2-ureidoacetamido)alkyl derivatives as formyl peptide receptor 2 modulators |
| EP3305763B1 (en) | 2013-11-28 | 2019-07-24 | Kyorin Pharmaceutical Co., Ltd. | Deuterated or isotopically labeled urea derivatives or pharmacologically acceptable salts thereof useful as fprl-1 agonists |
| AU2016266190A1 (en) | 2015-05-27 | 2018-01-18 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| WO2016189877A1 (en) | 2015-05-27 | 2016-12-01 | Kyorin Pharmaceutical Co., Ltd. | Urea derivative or pharmacologically acceptable salt thereof |
| KR20180081528A (ko) | 2015-11-24 | 2018-07-16 | 브리스톨-마이어스 스큅 컴퍼니 | 심장 질환의 치료를 위한 포르밀-펩타이드 수용체 2/리폭신 a4 수용체 (fpr2/alx) 타겟팅 |
| US10717708B2 (en) | 2015-12-10 | 2020-07-21 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| WO2018217684A1 (en) * | 2017-05-22 | 2018-11-29 | Bristol-Myers Squibb Company | Novel use of a formyl peptide receptor 2/ lipoxin a4 receptor (fpr2/alx) agonist for treatment of heart failure |
| JP7094989B2 (ja) * | 2017-06-09 | 2022-07-04 | ブリストル－マイヤーズ スクイブ カンパニー | シクロプロピルウレアホルミルペプチド２受容体およびホルミルペプチド１受容体アゴニスト |
| EP3634956B1 (en) | 2017-06-09 | 2021-04-07 | Bristol-Myers Squibb Company | Aryl heterocyclic piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| WO2018227065A1 (en) | 2017-06-09 | 2018-12-13 | Bristol-Myers Squibb Company | Piperidinone formyl peptide 2 receptor and formyl peptide 1 receptor agonists |
| WO2019173182A1 (en) * | 2018-03-05 | 2019-09-12 | Bristol-Myers Squibb Company | Phenylpyrrolidinone formyl peptide 2 receptor agonists |
-
2018
- 2018-06-08 KR KR1020207000291A patent/KR102615095B1/ko active Active
- 2018-06-08 ES ES18735092T patent/ES2869129T3/es active Active
- 2018-06-08 US US16/619,960 patent/US11008301B2/en active Active
- 2018-06-08 EP EP18735092.1A patent/EP3634955B1/en active Active
- 2018-06-08 WO PCT/US2018/036624 patent/WO2018227058A1/en not_active Ceased
- 2018-06-08 CN CN201880050616.6A patent/CN110997652B/zh active Active
- 2018-06-08 JP JP2019568064A patent/JP7098663B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020523331A5 (enExample) | ||
| US10772893B2 (en) | 2-(morpholin-4-yl)-1,7-naphthyridines | |
| US10729680B2 (en) | 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines | |
| FI3932919T3 (fi) | Jak-inhibiittoriyhdiste ja sen käyttö | |
| CA2772790C (en) | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors | |
| CA2934137C (en) | Novel carboxamides, method for the production thereof, pharmaceutical preparations comprising them, and use thereof for producing medicaments | |
| JP6688735B2 (ja) | ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン | |
| JP2021516240A5 (enExample) | ||
| KR20140003436A (ko) | 과증식성 장애 및 혈관형성과 관련된 질환 치료에 유용한 아미노알코올 치환된 2,3-디하이드로이미다조[1,2-ｃ]퀴나졸린 유도체 | |
| CA3071760A1 (en) | Combination of atr kinase inhibitors and pd-1/pd-l1 inhibitors | |
| JP6001049B2 (ja) | Ｍｐｓ−１キナーゼ阻害剤としての置換ベンズイミダゾール類 | |
| WO2018077944A2 (en) | 4,5-annulated 1,2,4-triazolones | |
| PT2791136E (pt) | Triazolpiridinas substituídas e respectiva utilização como inibidores de ttk | |
| JP2015514806A5 (enExample) | ||
| CN103717604A (zh) | 取代的氨基咪唑并哒嗪 | |
| US20170334899A1 (en) | Amino-substituted isothiazoles | |
| JP2018536687A5 (enExample) | ||
| WO2017102091A1 (en) | Heteroarylbenzimidazole compounds | |
| WO2018153973A1 (en) | Combination of atr kinase inhibitors with parp inhibitors | |
| JP2017528515A5 (enExample) | ||
| JP2020503302A5 (enExample) | ||
| JP2015524843A5 (enExample) | ||
| JP6166289B2 (ja) | 置換イミダゾピリダジン | |
| WO2015113927A1 (en) | Amino-substituted isothiazoles | |
| US20170217946A1 (en) | Amino-substituted isoxazoles |